Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 204, Issue 1, Pages 60-64Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jir220
Keywords
-
Categories
Funding
- Peer-Reviewed Medical Research Program [W81XWH-04-1-0067]
- Johns Hopkins University School of Medicine General Clinical Research Center (National Center for Research Resources, National Institutes of Health) [M01-RR00052]
Ask authors/readers for more resources
Human challenges with enterotoxigenic Escherichia coli (ETEC) have broadened our understanding of this important enteropathogen. We report findings from the first challenge studies using ETEC-expressing colonization factor fimbria CS17 and CS19. LSN03-016011/A (LT, CS17) elicited a dose-dependent effect, with the upper dose (6 x 10(9) organisms) causing diarrhea in 88% of recipients. WS0115A (LTSTp, CS19) also showed a dose response, with a 44% diarrhea rate at 9 x 10(9) organisms. Both strains elicited homologous antifimbrial and anti-LT antibody seroconversion. These studies establish the relative pathogenicity of ETEC expressing newer class 5 fimbriae and suggest suitability of the LT|CS17-ETEC challenge model for interventional trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available